
Opinion|Videos|September 16, 2024
BTK Inhibitor-Associated Adverse Events
The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
2
Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists
3
Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma
4
Single-Shot Respiratory Vaccine Could Transform Pharmacist Counseling and Immunization Rates
5







































































































